A detailed history of Susquehanna International Group, LLP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Susquehanna International Group, LLP holds 34,935 shares of ABUS stock, worth $110,394. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,935
Previous 192,081 81.81%
Holding current value
$110,394
Previous $480,000 81.25%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$2.26 - $2.92 $355,149 - $458,866
-157,146 Reduced 81.81%
34,935 $90,000
Q4 2023

Feb 14, 2024

SELL
$1.69 - $2.54 $27,641 - $41,544
-16,356 Reduced 7.85%
192,081 $480,000
Q3 2023

Nov 14, 2023

SELL
$1.9 - $2.27 $195,795 - $233,923
-103,050 Reduced 33.08%
208,437 $423,000
Q2 2023

Aug 11, 2023

BUY
$2.24 - $3.06 $330,606 - $451,631
147,592 Added 90.05%
311,487 $716,000
Q1 2023

May 16, 2023

SELL
$2.23 - $3.1 $291,351 - $405,018
-130,651 Reduced 44.36%
163,895 $496,000
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $9,519 - $14,204
4,984 Added 1.72%
294,546 $686,000
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $7,777 - $11,914
4,137 Added 1.45%
289,562 $553,000
Q2 2022

Aug 15, 2022

SELL
$1.98 - $3.17 $307,375 - $492,110
-155,240 Reduced 35.23%
285,425 $774,000
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $184,525 - $303,475
-76,250 Reduced 14.75%
440,665 $1.31 Million
Q4 2021

Feb 14, 2022

SELL
$3.11 - $4.61 $453,089 - $671,621
-145,688 Reduced 21.99%
516,915 $2.01 Million
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $1.07 Million - $1.87 Million
404,726 Added 156.95%
662,603 $2.84 Million
Q2 2021

Aug 11, 2021

SELL
$2.5 - $3.51 $1.03 Million - $1.44 Million
-411,234 Reduced 61.46%
257,877 $781,000
Q1 2021

May 17, 2021

BUY
$3.14 - $4.84 $831,308 - $1.28 Million
264,748 Added 65.47%
669,111 $2.23 Million
Q4 2020

Feb 16, 2021

BUY
$2.76 - $4.97 $564,213 - $1.02 Million
204,425 Added 102.24%
404,363 $1.44 Million
Q3 2020

Nov 16, 2020

BUY
$1.75 - $6.2 $52,552 - $186,186
30,030 Added 17.67%
199,938 $626,000
Q1 2020

May 15, 2020

BUY
$1.01 - $3.42 $106,718 - $361,364
105,662 Added 164.46%
169,908 $172,000
Q4 2019

Feb 14, 2020

BUY
$0.87 - $2.89 $44,600 - $148,155
51,265 Added 394.92%
64,246 $179,000
Q3 2019

Nov 14, 2019

SELL
$1.34 - $2.4 $37,006 - $66,280
-27,617 Reduced 68.03%
12,981 $20,000
Q2 2019

Aug 16, 2019

BUY
$1.46 - $4.44 $3,160 - $9,612
2,165 Added 5.63%
40,598 $84,000
Q2 2019

Aug 14, 2019

BUY
$1.46 - $4.44 $28,227 - $85,842
19,334 Added 101.23%
38,433 $80,000
Q4 2017

Feb 14, 2018

SELL
$4.45 - $7.7 $15,223 - $26,341
-3,421 Reduced 15.19%
19,099 $96,000
Q3 2017

Nov 14, 2017

BUY
$3.4 - $7.0 $76,568 - $157,640
22,520
22,520 $140,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $474M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.